Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex322a13a4c.htm |
| EX-31.2 - EX-31.2 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex312bf0888.htm |
| EX-31.1 - EX-31.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex311433cb7.htm |
| EX-23.1 - EX-23.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex2318fe4d9.htm |
| EX-21.1 - EX-21.1 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex211ece4e8.htm |
| EX-4.18 - EX-4.18 - Timber Pharmaceuticals, Inc. | bpmx-20200131ex418efc004.htm |
| 10-K - 10-K - Timber Pharmaceuticals, Inc. | bpmx-20200131x10k.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES‑OXLEY ACT OF 2002
In connection with the Annual Report of BioPharmX Corporation (the “Company”) on Form 10‑K for the fiscal year ended January 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002, that to the best of the officer’s knowledge:
|
1. |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
2. |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: March 23, 2020 |
|
|
|
|
|
|
/s/ STEVEN M. BOSACKI |
|
|
Steven M. Bosacki |
|
|
Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) |
|
|
|